Novel role of transglutaminase 1 in corpora amylacea formation?

Neurobiology of Aging

Volumn 32, Issue 5, 2011, Pages 845-856

  Wilhelmus, Micha M M ^a   Verhaar, Robin ^a   Bol, John G J M ^a   van Dam, Anne Marie ^a   Hoozemans, Jeroen J M ^a   Rozemuller, Annemieke J M ^a   Drukarch, Benjamin ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Aging; Alzheimer's disease; Corpora amylacea; Parkinson's disease; Protein cross linking; Transglutaminases

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BETA ACTIN; BETA TUBULIN; LIPOFUSCIN; NEUROMELANIN; PARKIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; TAU PROTEIN; TRANSGLUTAMINASE 1; UBIQUITIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AMYLOID BODY; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PARKINSON DISEASE; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SUBSTANTIA NIGRA; TEMPORAL CORTEX;

AGED; AGED, 80 AND OVER; AGING; ALZHEIMER DISEASE; CYTOSKELETAL PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOCORTEX; PARKINSON DISEASE; SUBSTANTIA NIGRA; TRANSGLUTAMINASES;

EID: 79954608346     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2009.04.019     Document Type: Article

References (72)

1. Andringa G., Lam K.Y., Chegary M., Wang X., Chase T.N., Bennett M.C. Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease. FASEB J. 2004, 18:932-934.
2. Bailey C.D., Johnson G.V. Developmental regulation of tissue transglutaminase in the mouse forebrain. J. Neurochem. 2004, 91:1369-1379.
3. Baumgartner W., Weth A. Transglutaminase 1 stabilizes beta-actin in endothelial cells correlating with a stabilization of intercellular junctions. J. Vasc. Res. 2007, 44:234-240.
4. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
5. Candi E., Schmidt R., Melino G. The cornified envelope: a model of cell death in the skin. Nat. Rev. Mol. Cell. Biol. 2005, 6:328-340.
6. Caron A., Gohel C., Mollaret K., Morello R., Chapon F. Study of some components of the cytoskeleton in muscular disorders with nonspecific cytoplasmic bodies. Acta Neuropathol. 1999, 97:267-274.
7. Cavanagh J.B. Corpora-amylacea and the family of polyglucosan diseases. Brain Res. Brain Res. Rev. 1999, 29:265-295.
8. Choi Y.C., Park G.T., Kim T.S., Sunwoo I.N., Steinert P.M., Kim S.Y. Sporadic inclusion body myositis correlates with increased expression and cross-linking by transglutaminases 1 and 2. J. Biol. Chem. 2000, 275:8703-8710.
9. Cisse S., Perry G., Lacoste-Royal G., Cabana T., Gauvreau D. Immunochemical identification of ubiquitin and heat-shock proteins in corpora amylacea from normal aged and Alzheimer's disease brains. Acta Neuropathol. 1993, 85:233-240.
10. Citron B.A., Suo Z., SantaCruz K., Davies P.J., Qin F., Festoff B.W. Protein crosslinking, tissue transglutaminase, alternative splicing and neurodegeneration. Neurochem. Int. 2002, 40:69-78.
11. Daniel S.E., Lees A.J. Parkinson's Disease Society Brain Bank, London: overview and research. J. Neural. Transm. Suppl. 1993, 39:165-172.
12. Dodson M.W., Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr. Opin. Neurobiol. 2007, 17:331-337.
13. Dudek S.M., Johnson G.V. Transglutaminase catalyzes the formation of sodium dodecyl sulfate-insoluble, Alz-50-reactive polymers of tau. J. Neurochem. 1993, 61:1159-1162.
14. Dudek S.M., Johnson G.V. Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide. Brain Res. 1994, 651:129-133.
15. Eckert R.L., Sturniolo M.T., Broome A.M., Ruse M., Rorke E.A. Transglutaminase function in epidermis. J. Invest. Dermatol. 2005, 124:481-492.
16. Feng J. Microtubule: a common target for parkin and Parkinson's disease toxins. Neuroscientist 2006, 12:469-476.
17. Fesus L. Biochemical events in naturally occurring forms of cell death. FEBS Lett. 1993, 328:1-5.
18. Fesus L., Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem. Sci. 2002, 27:534-539.
19. Folk J.E., Finlayson J.S. The epsilon-(gamma-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv. Protein Chem. 1977, 31:1-133.
20. Fukuda T., Tanaka J., Watabe K., Numoto R.T., Minamitani M. Immunohistochemistry of neuronal inclusions in the cerebral cortex and brain-stem in Lewy body disease. Acta Pathol. Jpn. 1993, 43:545-551.
21. Gati I., Leel-Ossy L. Heat shock protein 60 in corpora amylacea. Pathol. Oncol. Res. 2001, 7:140-144.
22. Glenner G.G., Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984, 120:885-890.
23. Greenberg C.S., Birckbichler P.J., Rice R.H. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991, 5:3071-3077.
24. Hartley D., Zhao C., Li S., Li Z., Walz T. Role of transglutaminase in amyloid-beta aggregation, stability and biologic activity. J. Biol. Chem. 2007, 284:16790-16800.
25. Hilbig H., Beier V., Koster K., Stoll C., Richter D., Dinse H.R. Enriched environmental conditions ameliorate age-dependent alterations in the somatosensory system, but do not affect the motor system of the rat spinal cord. Neuroembryol. Aging 2006, 4:138-146.
26. Hennings H., Steinert P., Buxman M.M. Calcium induction of transglutaminase and the formation of epsilon(gamma-glutamyl) lysine cross-links in cultured mouse epidermal cells. Biochem. Biophys. Res. Commun. 1981, 102:739-745.
27. Hurtig H.I., Trojanowski J.Q., Galvin J., Ewbank D., Schmidt M.L., Lee V.M., Clark C.M., Glosser G., Stern M.B., Gollomp S.M., Arnold S.E. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000, 54:1916-1921.
28. Iwaki T., Hamada Y., Tateishi J. Advanced glycosylation end-products and heat shock proteins accumulate in the basophilic degeneration of the myocardium and the corpora amylacea of the glia. Pathol. Int. 1996, 46:757-763.
29. Jensen P.H., Sorensen E.S., Petersen T.E., Gliemann J., Rasmussen L.K. Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide. Biochem. J. 1995, 310:91-94.
30. Johnson G.V., Cox T.M., Lockhart J.P., Zinnerman M.D., Miller M.L., Powers R.E. Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res. 1997, 751:323-329.
31. Junn E., Ronchetti R.D., Quezado M.M., Kim S.Y., Mouradian M.M. Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2047-2052.
32. Kahle P.J., Haass C. How does parkin ligate ubiquitin to Parkinson's disease?. EMBO 2004, 5:681-685.
33. Keller J.N. Age-related neuropathology, cognitive decline, and Alzheimer's disease. Aging Res. Rev. 2006, 5:1-13.
34. Kim S.Y., Grant P., Lee J.H., Pant H.C., Steinert P.M. Differential expression of multiple transglutaminases in human brain. Increased expression and cross-linking by transglutaminases 1 and 2 in Alzheimer's disease. J. Biol. Chem. 1999, 274:30715-30721.
35. Kimura T., Takamatsu J., Miyata T., Miyakawa T., Horiuchi S. Localization of identified advanced glycation end-product structures, N epsilon(carboxymethyl)lysine and pentosidine, in age-related inclusions in human brains. Pathol. Int. 1998, 48:575-579.
36. Konno T., Morii T., Hirata A., Sato S., Oiki S., Ikura K. Covalent blocking of fibril formation and aggregation of intracellular amyloidgenic proteins by transglutaminase-catalyzed intramolecular cross-linking. Biochemistry 2005, 44:2072-2079.
37. Konno T., Morii T., Shimizu H., Oiki S., Ikura K. Paradoxical inhibition of protein aggregation and precipitation by transglutaminase-catalyzed intermolecular cross-linking. J. Biol. Chem. 2005, 280:17520-17525.
38. Lee V.M., Balin B.J., Otvos L., Trojanowski J.Q. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 1991, 251:675-678.
39. Loeffler K.U., Edward D.P., Tso M.O. Tau-2 immunoreactivity of corpora amylacea in the human retina and optic nerve. Invest. Ophthalmol. Vis. Sci. 1993, 3:2600-2603.
40. Lorand L., Graham R.M. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell. Biol. 2003, 4:140-156.
41. Maccioni R.B., Seeds N.W. Transglutaminase and neuronal differentiation. Mol. Cell. Biochem. 1986, 69:161-168.
42. Martin J.E., Mather K., Swash M., Garofalo O., Leigh P.N., Anderton B.H. Heat shock protein expression in corpora amylacea in the central nervous system: clues to their origin. Neuropathol. Appl. Neurobiol. 1991, 17:113-119.
43. Masters C.L., Simms G., Weinman N.A., Multhaup G., McDonald B.L., Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl. Acad. Sci. U.S.A. 1985, 82:4245-4249.
44. Miller C.C., Anderton B.H. Transglutaminase and the neuronal cytoskeleton in Alzheimer's disease. J. Neurochem. 1986, 46:1912-1922.
45. Miller M.L., Johnson G.V. Transglutaminase cross-linking of the tau protein. J. Neurochem. 1995, 65:1760-1770.
46. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
47. Muma N.A. Transglutaminase is linked to neurodegenerative diseases. J. Neuropathol. Exp. Neurol. 2007, 66:258-263.
48. Nemes Z., Devreese B., Steinert P.M., Van B.J., Fesus L. Cross-linking of ubiquitin, HSP27, parkin, and alpha-synuclein by gamma-glutamyl-epsilon-lysine bonds in Alzheimer's neurofibrillary tangles. FASEB J. 2004, 18:1135-1137.
49. Nishiura H., Shibuya Y., Yamamoto T. S19 ribosomal protein cross-linked dimer causes monocyte-predominant infiltration by means of molecular mimicry to complement C5a. Lab. Invest. 1998, 78:1615-1623.
50. Norlund M.A., Lee J.M., Zainelli G.M., Muma N.A. Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res. 1999, 851:154-163.
51. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J. Cell. Mol. Med. 2008, 12:363-373.
52. Ogawa H., Goldsmith L.A. Human epidermal transglutaminase. Preparation and properties. J. Biol. Chem. 1976, 251:7281-7288.
53. Ramsey H.J. Ultrastructure of corpora amylacea. J. Neuropathol. Exp. Neurol. 1965, 24:25-39.
54. Sakai M., Austin J., Witmer F., Trueb L. Studies of corpora amylacea. I. Isolation and preliminary characterization by chemical and histochemical techniques. Arch. Neurol. 1969, 21:526-544.
55. Savage G., Ray F., Halmagyi M., Blazely A., Harper C. Stable neuropsychological deficits in adult polyglucosan body disease. J. Clin. Neurosci. 2007, 14:473-477.
56. Schipper H.M., Cisse S. Mitochondrial constituents of corpora amylacea and autofluorescent astrocytic inclusions in senescent human brain. Glia 1995, 14:55-64.
57. Schipper H.M., Vininsky R., Brull R., Small L., Brawer J.R. Astrocyte mitochondria: a substrate for iron deposition in the aging rat substantia nigra. Exp. Neurol. 1998, 152:188-196.
58. Segers-Nolten I., Wilhelmus M.M., Veldhuis G., van R.B., Drukarch B., Subramaniam V. Tissue transglutaminase modulates {alpha}-synuclein oligomerization. Protein Sci. 2008, 17:1395-1402.
59. Selkoe D.J. The molecular pathology of Alzheimer's disease. Neuron 1991, 6:487-498.
60. Selkoe D.J. Alzheimer's disease: genotypes, phenotypes, and treatments. Science 1997, 275:630-631.
61. Selmaj K., Pawlowska Z., Walczak A., Koziolkiewicz W., Raine C.S., Cierniewski C.S. Corpora amylacea from multiple sclerosis brain tissue consists of aggregated neuronal cells. Acta Biochim. Pol. 2008, 55:43-49.
62. Singer S.M., Zainelli G.M., Norlund M.A., Lee J.M., Muma N.A. Transglutaminase bonds in neurofibrillary tangles and paired helical filament tau early in Alzheimer's disease. Neurochem. Int. 2002, 40:17-30.
63. Singhrao S.K., Morgan B.P., Neal J.W., Newman G.R. A functional role for corpora amylacea based on evidence from complement studies. Neurodegeneration 1995, 4:335-345.
64. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
65. Tamo W., Imaizumi T., Tanji K., Yoshida H., Takanashi S., Wakabayashi K., Takahashi R., Hattori N., Satoh K. Parkin is expressed in vascular endothelial cells. Neurosci. Lett. 2007, 419:199-201.
66. Tani E., Evans J.P. Electron microscope studies of cerebral swelling. II. Alterations of myelinated nerve fibres. Acta Neuropathol. 1965, 4:604-623.
67. Tofaris G.K., Spillantini M.G. Physiological and pathological properties of alpha-synuclein. Cell. Mol. Life Sci. 2007, 64:2194-2201.
68. Trojanowski J.Q., Lee V.M. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann. NY Acad. Sci. 2003, 991:107-110.
69. Wang J.Z., Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog. Neurobiol. 2008, 85:148-175.
70. Wilhelmus M.M., Grunberg S.C., Bol J.G., van Dam A.M., Hoozemans J.J., Rozemuller A.J., Drukarch B. Transglutaminases and transglutaminase-catalyzed cross-links colocalize with the pathological lesions in Alzheimer's disease brain. Brain Pathol. 2008, doi:10.1111/j.1750-3639.2008.00197.
71. Zatloukal K., Fesus L., Denk H., Tarcsa E., Spurej G., Bock G. High amount of epsilon-(gamma-glutamyl)lysine cross-links in Mallory bodies. Lab. Invest. 1992, 66:774-777.
72. Zemaitaitis M.O., Kim S.Y., Halverson R.A., Troncoso J.C., Lee J.M., Muma N.A. Transglutaminase activity, protein, and mRNA expression are increased in progressive supranuclear palsy. J. Neuropathol. Exp. Neurol. 2003, 62:173-184.